Tags : Numab

Eisai Signs a Research and Option Agreement with Numab to

Shots: Numab to receive up front, research funding, success fees, milestones & royalties on sales. Eisai to get an option to acquire an exclusive license to develop and commercialize novel multi-specific antibody-based molecules developed utilizing Numab’s MATCH platform The focus of the agreement is to leverage Numab’s multi-specific technology to generate cancer therapies providing superior […]Read More